CLINUVEL update on Level II ADR upgrade, Nasdaq uplist
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Clinuvel Pharmaceuticals Limited has announced its ongoing engagement with the U.S. Securities and Exchange Commission regarding its draft registration statement for upgrading its American Depository Receipt program to Nasdaq Level II. The company expects the SEC review to conclude before the end of the financial year, allowing for the planned uplisting under the ticker CUVL. Clinuvel emphasizes that no final decision has been made regarding the uplisting, which remains subject to SEC review and Nasdaq requirements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallClinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- FDA relaxes SCENESSE postmarketing requirement
- CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
- Final EMA scientific advice for pivotal Phase III vitiligo
- CLINUVEL's global programs showcased at AAD
- Chair Letter to Shareholders
Later from Clinuvel Pharmaceuticals
- CLINUVEL publicly files 20-F to U.S. SEC
- SCENESSE approved for EPP in Canada
- CLINUVEL strategic reorganisation to refocus on U.S. markets
- CLINUVEL implements strategic reorganisation to refocus on U.S. markets
- Update - SCENESSE in vitiligo
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals